Status:
TERMINATED
Efficacy of Retreatments With Intravitreal Bevacizumab
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Age Related Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
60-95 years
Phase:
PHASE3
Brief Summary
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a sign...
Eligibility Criteria
Inclusion
- \* Any visual acuity
- OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
- Active angiogram leakage
Exclusion
- \* Basal Inflammatory disease
- Endoftalmitis history
- Lesions bigger than 5400 u or with scarring greater than 50% of lesion.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00406744
Start Date
May 1 2006
End Date
November 1 2006
Last Update
June 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asociacion para Evitar la Ceguera en Mexico
Mexico City, Mexico City, Mexico, 04030